EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases

Daifei Shen iD, Runji Chen iD, Shu Ye iD

Research · 01.01.2026 · 9

DOI: 10.34133/research.1373 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Research, online erschienen am 23.07.2026. Verfasst von Daifei Shen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Translational Medicine, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidemiological and clinical evidence increasingly highlights a close association between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular disease (CVD). The transition from nonalcoholic fatty liver disease (NAFLD) to MASLD represents a conceptual shift toward a metabolism-centered framework with important implications for cardiovascular risk assessment. As the global burden of both conditions continues to rise, clarifying their bidirectional relationship has become increasingly important. This review summarizes current epidemiological and clinical evidence linking MASLD to adverse cardiovascular outcomes and discusses the potential value of liver-specific markers, particularly fibrosis indices, in cardiovascular risk stratification beyond traditional risk factors. Mechanistically, we examine shared upstream metabolic mechanisms linking MASLD and CVD, as well as the bidirectional liver–heart axis involving liver-to-heart effects and cardiovascular feedback to the liver. We further summarize key molecular mediators involved in these processes and their potential relevance to both cardiovascular and hepatic injury. Finally, we discuss the clinical and therapeutic implications of this integrated framework, including the potential to achieve dual hepatic and cardiovascular benefit. A clearer understanding of the MASLD–CVD interplay may support earlier detection, more precise risk stratification, and multidisciplinary management.

Autor:innen und Institutionen

  • Research Center of Translational Medicine, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Department of Cardiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Department of Basic Medicine, Shantou University Medical College, Shantou, China.
  • Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK.
  • Cardiovascular-Metabolic Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Daifei Shen, Runji Chen, Shu Ye

Zitieren

APA

Shen, D., Chen, R., & Ye, S. (2026). Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases. Research, 9. https://doi.org/10.34133/research.1373

Vancouver

Shen D, Chen R, Ye S. Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases. Research. 2026;9. doi:10.34133/research.1373

BibTeX
@article{Shen2026,
  author = {Shen, Daifei and Chen, Runji and Ye, Shu},
  title = {Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases},
  journal = {Research},
  year = {2026},
  volume = {9},
  doi = {10.34133/research.1373}
}
Kostenlos starten →